Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Otezla | Apremilast | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Oxervate | cenegermin | Neurotrophic keratitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Oxlumo | lumasiran | Primary hyperoxaluria type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
Ozanex | ozenoxacin | Impetigo | Do not reimburse | Complete | ||
Ozempic | semaglutide | Diabetes mellitus, type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Ozurdex | dexamethasone intravitreal implant | Diabetic macular edema | Do not reimburse | Complete | ||
Ozurdex | dexamethasone intravitreal implant | Non-infectious uveitis | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Ozurdex | dexamethasone | Diabetic macular edema | Do not reimburse | Complete | ||
Ozurdex | Dexamethasone intravitreal implant | Macular edema, central retinal vein occlusion | Do not list | Complete | ||
Padcev | enfortumab vedotin | Locally advanced or metastatic urothelial carcinoma | Reimburse with clinical criteria and/or conditions | Complete |